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ABSTRACT
Objective: To conduct a randomized, sham-controlled phase I/IIa study to evaluate the safety and
preliminary efficacy of deep brain H-coil repetitive transcranial magnetic stimulation (rTMS) over
the prefrontal cortex (PFC) and the primary motor cortex (MC) in patients with MS with fatigue or
depression (NCT01106365).
Methods: Thirty-three patients with MSwere recruited to undergo 18 consecutive rTMS sessions
over 6 weeks, followed by follow-up (FU) assessments over 6weeks. Patients were randomized to
receive high-frequency stimulation of the left PFC, MC, or sham stimulation. Primary end point
was the safety of stimulation. Preliminary efficacy was assessed based on changes in Fatigue
Severity Scale (FSS) and Beck Depression Inventory scores. Randomization allowed only analysis
of preliminary efficacy for fatigue.
Results: No serious adverse events were observed. Five patients terminated participation during
treatment due to mild side effects. Treatment resulted in a significant median FSS decrease of
1.0 point (95%CI [0.45,1.65]), which was sustained during FU.
Conclusions: H-coil rTMS is safe and well tolerated in patients with MS. The observed sustained
reduction in fatigue after subthreshold MC stimulation warrants further investigation.
ClinicalTrials.gov identifier: NCT01106365.
Classification of evidence: This study provides Class III evidence that rTMS of the prefrontal or pri-
mary MC is not associated with serious adverse effects, although this study is underpowered to
state this with any precision. Neurol Neuroimmunol Neuroinflamm 2018;5:e423; doi: 10.1212/
NXI.0000000000000423
GLOSSARY
ANOVA 5 analysis of variance; BDI-IA 5 Beck Depression Inventory IA; BL 5 baseline; EDSS 5 Expanded Disability
Status Scale; FSMC 5 Fatigue Scale for Motor and Cognitive Functions; FSS 5 Fatigue Severity Scale; 9-HPT 5 9 Hole
Peg Test; IQR5 interquartile range;MC5motor cortex;MDD5major depressive disorder;MFIS5Modified Fatigue Impact
Scale; MSFC 5 multiple sclerosis functional composite; PASAT 5 Paced Auditory Serial Addition Test; PFC 5 prefrontal
cortex; RMT 5 resting motor threshold; rTMS 5 repetitive transcranial magnetic stimulation; SAE 5 serious adverse event;
T25FW 5 timed 25-ft walk.
MS is the most common autoimmune inflammatory and neurodegenerative disease of the
CNS.1 Fatigue is one of the most frequent symptoms experienced in MS, affecting up to
90% of patients.2 Although MS fatigue contributes to poor health-related quality of life3 and
is a major factor in disease-related unemployment,4 its etiology has not yet been fully elucidated,
and efficacious treatment options are scarce. Neuroimaging studies suggest that structural and
functional connectivity alterations, particularly to interconnections between the basal ganglia
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and the prefrontal cortex (PFC), the posterior
cingulate cortex and cortical motor areas, may
contribute to fatigue in MS.5–9
A potential treatment of functional connec-
tivity impairment is noninvasive neuromodu-
lation by means of repetitive transcranial
magnetic stimulation (rTMS). High-
frequency rTMS of the left PFC has been
demonstrated as safe and efficacious in major
depressive disorder (MDD).10 Moreover,
5-Hz rTMS applied to the primary motor cor-
tex (MC) improved lower limb spasticity11 and
bladder dysfunction12 in patients with MS.
rTMS using H-coils, a technology devel-
oped several years later, allows brain stimula-
tion 3 times deeper than that of standard
figure-of-eight coils at the expense of focal-
ity.13,14 It has also been widely proven as safe
and well tolerated, including in a study of
healthy volunteers15 and, in the form of
high-frequency stimulation of the left PFC,
as effective and safe treatment of MDD.16–18
PFC and MC stimulation directly targets cir-
cuits for which alterations in fatigue were re-
ported,5–9 and PFC stimulation is supported
by the high overlap between fatigue and
depressive symptoms.19 MC stimulation, on
the other hand, may also lead to an additional
improvement of fatigue via reduction of
spasticity.11
Against this background, we conducted
a randomized, sham-controlled phase I/IIa
pilot study to evaluate the safety, tolerability,
and preliminary efficacy of deep brain H-coil
rTMS over the left PFC and MC as treatment
of fatigue and depression in MS.
METHODS Study design and participants. The study was
designed as a prospective, randomized, semi-blinded, sham-con-
trolled phase I/IIa pilot study involving 2MS centers (NeuroCure
Clinical Research Center, Charité–Universitätsmedizin Berlin,
Germany, and the Institute of Neuroimmunology and Multiple
Sclerosis research at the University Hospital Hamburg Eppen-
dorf, Hamburg, Germany). Primary end point in this study was
safety of rTMS stimulation in patients withMS. The study design
and workflow are presented in figure 1. Patients underwent an
initial screening/baseline (BL) visit 4 weeks before intervention,
from which all BL characteristics were derived and a second
scheduling visit to confirm study inclusion or exclusion and to
schedule an appointment for commencement of the intervention
2 weeks later. Patients were then randomized into 3 groups on the
day of treatment initiation, followed by 6 weeks of intervention.
After the treatment phase, patients were followed up every
2 weeks over 6 weeks (follow-ups: FU1, 2, and 3). Recruitment
period was from May 2010 to March 2011. This pilot trial was
performed without sample size calculation; randomization of 33
patients was planned. Recruitment was stopped regularly after
randomizing 33 patients. The study provides Class III evidence.
Inclusion criteria were diagnosis of MS according to the 2005
revised McDonald criteria,20 either a score of $4 on the Fatigue
Severity Scale (FSS)21 or a score of $12 on the Beck Depression
Inventory IA (BDI-IA),22 age (18–65 years), relapse-free for at
least 3 months, and free of steroid treatment within 30 days prior
to inclusion, Expanded Disability Status Scale (EDSS) between
0.0 and 6.0, stable immunotherapy or antidepressant therapy for
at least 3 months if applicable, and highly effective methods of
contraception for females. Exclusion criteria were history of seiz-
ures (personal or family), history of stroke, head injury, metal
fragments in the head, implanted devices such as cardiac pace-
makers, cochlear implants, medical pumps, alcohol or drug abuse,
pregnancy, comedication with neuroleptics or tricyclic antide-
pressants, increased intracranial pressure, bipolar affective disor-
der, significant neurologic, psychiatric, cardiovascular, hepatic,
renal, gastrointestinal, metabolic, or other systemic
comorbidities.
Abortion criteria were personal wish of the participant, any
relapse, exacerbation of depressive symptoms including suicidality
and suicide attempt, comedication with tricyclic antidepressant,
pregnancy, safety concerns, noncompliance, loss to FU, and miss-
ing more than 3 treatment sessions.
Standard protocol approvals, registrations, and patient
consents. The study was registered at clinicaltrials.gov as
NCT01106365 and was approved by the local ethics committees
of the Charité–Universitätsmedizin Berlin and by the Hamburg
Board of Physicians. It was conducted in accordance with the
Declaration of Helsinki and the guidelines of the International
Conference on Harmonisation of Good Clinical Practice. All
participants provided written informed consent.
Randomization and masking. Patients were randomized in
a 1:1:1 ratio to receive H6 coil rTMS over the left prefrontal
cortex (“PFC” group), sham rTMS over the same area (“PFC
sham” group), or H10 coil rTMS over the primary motor cortex
bilaterally (“MC” group). For randomization, Brainsway Ltd.
created individual treatment cards, which guaranteed blinding.18
Patients were enrolled in each center and assigned to groups using
the treatment cards by independent operators. The PFC sham
condition induced superficial magnetic sensations comparable to
the 2 therapeutic stimulation conditions, preventing patients from
distinguishing sham treatment by sensation or hearing. For PFC
and PFC sham conditions, both patients and operators were
blinded (double-blinded condition). For theMC stimulation, a dif-
ferent coil without extra sham function was used, thus operator
blinding was not possible. Thus, TMS operators were aware of the
MC stimulation condition, whereas the patients as well as inter-
viewing and examining neurologists were not (single blinded).
Diagnostic procedures. During treatment and follow-up,
a trained neurologist, who was masked to treatment allocation,
conducted a weekly and biweekly clinical interview and physical
examination, respectively, of each patient to assess safety and
tolerability. Moreover, patients were advised to contact the study
centers by phone or present to emergency services in case of severe
adverse events. We a priori defined any seizure or MS relapse as
serious adverse events (SAEs). Second, reports of the previous
week’s symptoms were assessed to calculate the FSS21 and the
BDI-IA22 questionnaire as indicator of preliminary clinical effi-
cacy. Patients with an FSS score of $4 were classified as
fatigued.21,23 Patients with a BDI score of $12 were classified as
depressed.22
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In addition, the EDSS24 and the multiple sclerosis functional
composite (MSFC), including the timed 25-ft walk (T25FW)
test, the 9-Hole Peg Test (9-HPT), and the Paced Auditory Serial
Addition Test (PASAT), were assessed at screening and in the
final FU visit.25 MSFC Z-scores were calculated from T25FW,
9-HPT, and PASAT results with reference to the screening exam-
ination including all patients.25
Transcranial magnetic stimulation. rTMS was performed by
3 operators using H-coils (Brainsway Ltd., Jerusalem, Israel)
connected to a Magstim Rapid2 stimulator (Magstim, Spring
Gardens, United Kingdom). Each participant received 3 rTMS
sessions per week over a period of 6 weeks (total of 18 treatments)
followed by a 6-week FU period comprising biweekly clinical
assessments and questionnaires.
Figure 1 Patient flow diagram
Patient flow in this interventional study. The column on the left side lists the week relative to the first day of intervention. The second column lists the diag-
nostic parameters assessed at the visits. The column on the right side depicts the patient flow including randomization in the 3 treatment groups. BDI-IA 5
Beck Depression Inventory IA; EDSS 5 Expanded Disability Status Scale; FSS 5 Fatigue Severity Scale; MC 5 motor cortex; MSFC 5 Multiple Sclerosis
Functional Composite; PFC 5 prefrontal cortex; rTMS 5 repetitive transcranial magnetic stimulation.
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Bilateral MC stimulation in the “MC” group was performed with
the H10 coil, designed for the activation of hand or leg MC. We
applied 40 trains of bihemispherical stimulation of the MC, with
bursts of 20 stimuli with an intertrain interval of 20 seconds at a fre-
quency of 5 Hz (intensity of 90% resting motor threshold [RMT])
with a total number of 800 stimuli and a total duration of 16 minutes,
positioning the center of the coil mid-sagittally over the primary MC.
Real left PFC stimulation in the “PFC” group was performed
with the left H6 coil, designed for the activation of superficial and
deep left PFC structures. To determine the individual RMT, the
coil center was positioned over the motor hand area, and contra-
lateral motor responses of the first dorsal interosseous muscle were
recorded. Individual RMT was defined as the minimum intensity
that evoked a potential of 50 mV in 5 of 10 consecutive stimuli
according to current international recommendations.26 The coil
was positioned 5 cm anteriorly to the left motor hot spot, parallel
to the sagittal suture of the skull in order to provide stimulation of
the left PFC region. We applied a total of 50 trains (intensity of
120% of RMT) in each session, with a duration of 2 seconds at
a frequency of 18 Hz repeating at 20-second intervals (total num-
ber of stimuli per session: 1,800; duration: 18 minutes).
The H6 coil but not the H10 coil included a sham function.
Superficial skin stimulation with a sham function, which led to
a comparable sound and sensation like real TMS, was ensured,
but not stimulation of the brain. For sham stimulation, the coil
was placed identically to the real PFC stimulation condition. Fifty
trains of superficial stimulation of the skin were applied at the
same frequency (18 Hz) and duration (2 seconds) at 20-second
intervals, as in the PFC stimulation paradigm (total number of
stimuli per session: 1,800; duration: 18 minutes).
Statistical analysis. Results are reported as frequencies and per-
centages, median, and interquartile range (IQR), depending on
the scale of the data. Baseline differences between PFC, PFC
sham, and MC groups including all patients completing the trial
were analyzed with nonparametric Kruskal-Wallis tests for ordi-
nal and continuous data and with Fisher-Freeman-Halton exact
tests for categorical data (table 1).
Clinical outcomes were FSS, BDI-IA, EDSS, and MSFC data
assessed at BL, FU1, and FU3 visits (for FSS and BDI-IA) or
FU3 (for EDSS and MSFC). FU1 FSS scores were not collected
for 3 PFC, 1 MC-, and 1 PFC sham–stimulated patients, and
BDI data for 2 PFC, 1 MC-, and 1 PFC sham–stimulated patients.
Here, data from the next FU visit were used. For 1 PFC- and 1MC-
stimulated patient, the third FU score had to be used. Patients whose
FU1 data were replaced with FU3 data were excluded in the pre-
liminary sustainability analysis, comparing the first and last FU data.
We analyzed preliminary clinical efficacy and sustainability in an
exploratory analysis using nonparametric (rank based) analysis of
variance (ANOVA)-like computation of longitudinal data in facto-
rial settings (R-package “nparLD”). The Wilcoxon signed-rank test
was used for pairwise post hoc analysis of changes over time within
each treatment group. The analysis of potential effects on fatigue
included only those patients who were classified as fatigued (FSS
$4.0) at BL. Distribution of patients classified as depressed (BDI-IA
.12.0) was uneven between the groups (table 1). We, therefore,
abstained from further analyzing effects on depressive symptoms. To
account for potential differences in fatigue and depression at BL
between groups as potential confounders, we additionally performed
a nonparametric (rank-based) ANOVA-like analysis for FSS score at
FU1 visit, with adjustment for FSS and BDI values at BL.
Table 1 Cohort overview at baseline
PFC PFC Sham MC p Valuea
Condition Treatment Sham Treatment
Patients n 9 10 9
Disease course RRMS/SPMS 8/1 9/1 9/0 1.000
Sex M/F 3/7 2/7 1/8 0.845
Age, y Median (IQR) 47 (32 to 51) 41 (39 to 45) 46 (42 to 48) 0.323
Time since diagnosis, mo Median (IQR) 46 (37 to 110) 67 (38 to 224) 187 (91 to 258) 0.048
EDSS Median (IQR) 2.5 (2.0 to 3.0) 3.0 (2.5 to 3.0) 2.5 (2.5 to 3.5) 0.719
T25FW, s Median (IQR) 7.2 (6.1 to 9.5) 9.6 (6.5 to 11.7) 8.1 (6.3 to 8.7) 0.365
9-HPT dom., s Median (IQR) 20.0 (18.7 to 21.0) 19.4 (17.5 to 23.6) 18.9 (18.5 to 21.1) 0.916
9-HPT ndom., s Median (IQR) 20.0 (19.5 to 22.7) 20.3 (18.5 to 22.8) 20.9 (19.3 to 21.9) 0.864
PASAT, /60 Median (IQR) 56 (53 to 59) 45 (40 to 48) 51 (44 to 53) 0.102
MSFC-Z Median (IQR) 0.5 (0.2 to 1.0) 20.1 (20.6 to 0.0) 0.0 (20.1 to 0.4) 0.131
BDI-IA Median (IQR) 22.0 (19.0 to 26.0) 14.0 (13.0 to 21.0) 12.0 (9.0 to 13.0) 0.002
BDI-IA >12 Yes/no 9/0 8/2 4/5 0.023
Antidepressant Tx Yes/no 5/4 5/5 1/8 0.119
FSS Median (IQR) 6.2 (5.3 to 6.3) 6.0 (4.6 to 6.1) 6.0 (5.6 to 6.4) 0.501
FSS ‡4.0 Yes/no 9/0 9/1 9/0 1.000
Abbreviations: 9-HPT 5 9-hole peg test of the dominant hand; 9-HPT ndom. 5 9-Hole Peg Test of the nondominant hand;
BDI-IA 5 Beck Depression Inventory IA; EDSS 5 Expanded Disability Status Scale; FSS 5 Fatigue Severity Scale; IQR 5
interquartile range (25th and 75th percentiles); MC 5 motor cortex MSFC 5 multiple sclerosis functional composite;
PASAT5 paced auditory serial additions test; PFC5 prefrontal cortex; RRMS5 relapsing-remitting MS; rTMS5 repetitive
transcranial magnetic stimulation; SPMS 5 secondary progressive MS; T25FW 5 Timed 25-ft walk.
a For categorical data derived from Fisher exact tests with Freeman-Halton extension, all other data from Kruskal-Wallis
tests. Significant p values are printed in bold.
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Statistical analyses were performed using IBM SPSS Statistics
software version 23 (IBM Corp., Armonk, NY), SAS 9.4 software
(SAS Institute Software GmbH, Vienna, Austria), and R software
version 3.2.4.27 All tests were 2 sided, and statistical significance
was determined at an a level of 0.05. Exploratory analyses had no
previous sample size calculation, and no adjustment for multiple
comparisons was applied.
RESULTS Patients. Thirty-seven patients with MS
were assessed for eligibility. Four patients did not
meet the inclusion criteria (figure 1). Of the remain-
ing 33 patients, 5 dropped out before completion.
Twenty-eight patients completed the treatment and
FU phases. Detailed BL demographic and clinical
data are presented in table 1. Eleven patients were on
stable antidepressant therapy (5 citalopram, 2 fluox-
etine, 2 venlafaxine, 1 sertraline, and 1 St. John wort
[Hypericum perforatum]). Two patients in the MC
group received symptomatic treatment with mod-
afinil. Baseline data were similar across groups for
disease course, age, sex, EDSS, and MSFC (table 1).
Safety and tolerability. No SAE were observed in any
group; however, known trigeminal neuralgia intensi-
fied in 1 PFC sham patient. Twenty-five of 28 pa-
tients reported at least 1 adverse event during the
entire treatment period, while 1 sham patient and 2
patients with MC did not (table 2). The adverse event
frequency of each group was too low to allow for
comparative analysis (table 2), and all patients fully
recovered from AEs within a few days.
All 5 premature dropouts occurred during the
treatment phase: 1 due to intensification of known
trigeminal neuralgia, 3 (1 from each treatment group)
due to scalp discomfort or headache during treatment
(and, in 1 case, due to time constraints after the initial
four treatments), and, last, 1 patient because of claus-
trophobia experienced under the stimulation device.
Exploratory clinical efficacy.Twenty-seven of 28 patients
(96.4%) were classified as fatigued at BL with an FSS
score of 4.0 or more (9 patients per group, table 1), of
which 7 (7/27 5 25.9%) were nonfatigued at the final
FU (3 sham-, 1 PFC-, and 3 MC-stimulated patients).
The single nonfatigued patient at BL (FSS 5 2.8) was
subsequently assessed as fatigued (FSS5 5.7) after PFC
sham stimulation (see also figure e-1, http://links.lww.
com/NXI/A2 for individual data curves). There was no
significant FSS difference at BL between the treatment
groups (table 1).
All patients with fatigue at BL showed significant
improvement after treatment (FU1, figure 2). Calcu-
lated at the group level, the median FSS score
decreased by 1.0 points (BL vs FU1, 95% CI 0.45–
1.65; time effect: df 5 1.0, p , 0.001). This
improvement was most evident in the MC group
(1.74 points, 95% CI 0.41–2.95) compared with
the PFC sham group (0.77 points, 95% CI 0.10–
2.30) and the PFC group (0.35, 95% CI 20.35 to
1.70). However, FSS scores did not differ between
treatment groups at BL or FU (FU1) (median FSS
scores at FU1 [IQR] 6.3 [4.7–6.7] PFC group; 5.2
[3.9–5.6] PFC sham group; 4.4 [3.8–4.7] MC stim-
ulation; nonparametric ANOVA-like analysis of BL
vs FU1 group effect: df 5 1.8, p 5 0.279). In addi-
tion, FSS scores were still significantly lower 4 weeks
later, at FU3 compared with BL (median decrease of
the FSS score of 1.1 points, 95% CI 0.55–1.68; time
effect: df 5 1.0, p , 0.001, group effect: df 5 1.9,
p 5 0.260), with the MC group (1.78 points, 95%
CI 0.85–2.75) continuing to show more improve-
ment compared with the PFC group (0.75, 95%
CI 20.20 to 1.94) and PFC sham (0.41 points,
95% CI 20.35 to 1.8) group (interaction group 3
time df 5 2.0, p 5 0.037). Indeed, the fatigue score
did not change significantly between FU1 and FU3
over all groups (median difference ,0.01 points,
95% CI 20.40 to 0.35), and there were no signifi-
cant differences in the changes over time between
groups (group 3 time, df 5 1.9, p 5 0.073; figure
2). EDSS and MSFC showed no significant change
over time or between groups (data not shown). We
obtained a significant impact of treatment group on
FSS scores at FU1 (p 5 0.001) and also a significant
Table 2 Adverse events
Reported events
Total PFC
PFC
Sham MC
n % n % n % n %
Increased headache during treatment 3 11 2 22 1 10 0 0
Headache on the day of treatment
Mild 2 7 1 11 0 0 1 11
Middle 10 36 4 44 5 50 1 11
Intense 1 4 1 11 0 0 0 0
Headache on following days
Mild 3 11 2 22 1 10 0 0
Middle 1 4 1 11 0 0 0 0
Intense 1 4 1 11 0 0 0 0
Paresthesia or pain of lower limb 10 36 4 44 3 30 3 33
Paresthesia of upper limb 6 21 1 11 3 30 2 22
Increased bladder spasticity 1 4 1 11 0 0 0 0
Unspecific facial pain 4 14 0 0 3 30 1 11
Restless legs/spasticity over night 3 11 2 22 0 0 1 11
Gait disturbance 2 7 0 0 1 10 1 11
Dizziness 1 4 0 0 1 10 0 0
Tiredness on the day following treatment 2 7 0 0 0 0 2 22
Dorsal pain 1 4 0 0 1 10 0 0
Unspecific feeling of discomfort 2 7 1 11 1 10 0 0
Abbreviations: MC 5 motor cortex; PFC 5 prefrontal cortex.
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impact of FSS at BL (p 5 0.015), but not of BDI at
BL (p 5 0.848) in nonparametric (rank-based)
ANOVA-like analysis, confirming our findings with-
out these covariates.
DISCUSSION This randomized, sham-controlled
phase I/IIa study applied stimulation of deeper
brain regions by means of interventional H-coil
rTMS to patients with MS. We found that rTMS is
safe in MS, and preliminary efficacy data further
support investigating rTMS for symptomatic treat-
ment of fatigue in MS. Approximately one-third of
patients suffered from mild-to-moderate headache,
which was the most frequently experienced adverse
event, all of which were fully resolved within several
days. The adverse events were distributed equally
across treatment groups. In line with other clinical
studies using rTMS, transient headache and scalp
discomfort were the most frequently reported side
effects.28 Fifteen percent of patients discontinued
before completion of the study, with the majority (3
of 5 patients) reporting scalp discomfort and head-
ache as reasons. These data are instructive for the
design of future trials, particularly for the calculation
of sample size and obtaining the consent of study
participants.
Our exploratory analysis showed that rTMS sig-
nificantly reduced fatigue in our cohort of 27 pa-
tients. This effect was most pronounced in the MC
stimulation group, with a median decrease of 1.74
points in the FSS score directly after treatment com-
pared with BL, which should be considered clinically
meaningful.29 While the results are promising, they
have to be interpreted with caution, given the small
sample size and the exploratory nature of the study
and of the efficacy analysis.
H-coil enables nonfocal stimulation of deeper neu-
ronal structures as compared to standard figure-of-eight
coils.13,14 This may be an advantage when the therapeu-
tic approach aims at targeting larger brain regions that
are presumably involved in the pathophysiology of
MDD (e.g., the lateral PFC, including the broader
dorsolateral and ventrolateral PFC areas and their pro-
jections into subcortical networks18). Recent concepts
propose that fatigue in MS is a network disorder asso-
ciated with impaired functional connectivity. These
connectivity alterations are thought to result from focal
or diffuse tissue damage, with altered microstructural
integrity of white matter tracts and gray matter.8,30,31
Disease-related disruption of interconnections between
critical anatomical regions, such as the basal ganglia
with the PFC, the posterior cingulate cortex, or cortical
motor areas, may result in profoundly altered striato-
cortical connectivity. This, in turn, may impair motor
(e.g., planning and execution of movements) and non-
motor (e.g., motivation and reward processing) func-
tions, thus contributing to the pathophysiology of
fatigue in MS.8,31 The network theory of MS fatigue
is supported by numerous structural and functional
neuroimaging studies and electrophysiologic investiga-
tions.8,32,33 As these regions are within the reach of the
H-coil, it is conceivable that deep TMS may at least in
part and temporarily normalize the impaired functional
connectivity and thus improve fatigue—similar to
mechanisms thought to be involved in the reduction
of depressive symptoms in MDD following rTMS.18
Although we found improvement in fatigue in both
verum stimulation conditions, the decrease in fatigue
severity was more pronounced following bilateral
MC stimulation. Given the broad coverage of the
H-coil, the MC stimulation paradigm may possibly
have influenced the activity of additional brain regions
beyond motor areas. However, by generating a facilita-
tory input on primary motor and supplementary MC
areas, as has been previously demonstrated for rTMS
at 5 Hz,11 our stimulation paradigm may have amelio-
rated impaired recruitment patterns of supplementary
motor areas, which are associated with fatigue.9
In contrast to previous studies, acute rTMS treat-
ment in our study was not followed by a maintenance
protocol.18 Despite this, FSS did not return to BL
levels during the entire 6-week FU phase, which is
in line with reported sustained long-term effects for
approximately 5 months in patients with MDD in an
open label study.34 The sustained effect without the
maintenance protocol suggests that clinical rTMS
protocols for MS fatigue could involve fewer stimu-
lation sessions18 following an initial induction phase,
thereby reducing patients’ burden of frequent visits to
the clinic.
Figure 2 Changes in fatigue under treatment
FSS changes during the study using standard boxplots. Treatment group “PFC” is shown in
purple, treatment group “MC” in green, and sham group “PFC sham” in gray. Post-treatment
visits are termed “follow-up” (plus follow-up visit number). The yellow line indicates FSS
cutoff between fatigued (FSS $ 4) and nonfatigued values. FSS 5 Fatigue Severity Scale;
MC 5 motor cortex; PFC 5 prefrontal cortex.
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This study prioritized the assessment of safety and
tolerability as a primary end point at the expense of
investigating preliminary efficacy. Thus, all data on
the effects of rTMS on MS-associated fatigue are pre-
liminary and should be interpreted with caution. Pla-
cebo effects of rTMS may also lead to a relevant
reduction of symptoms as observed in previous rTMS
studies.35 Furthermore, as our sham condition used
the stimulation parameters of active PFC rTMS, but
not MC, potential sensory side effects of sham (for
example, alertness caused by auditory stimuli such as
the frequency of the clicking sound) were controlled
for PFC, but not for MC. To confirm our data, fur-
ther studies should use stimulation parameters adap-
ted to sham control for MC stimulation.
Fatigue can affect cognitive and motor aspects dif-
ferently, which lead to the conceptualization of cogni-
tive fatigue and motor fatigue as potentially
independent constructs. Thus, some instruments,
e.g., the Modified Fatigue Impact Scale (MFIS) dif-
ferentiates motor, cognitive, and psychosocial fatigue
in its subscales.36 The FSS scale used in our study
does not differentiate between cognitive and motor
aspects, but treats fatigue as its own entity, which can
affect both motor and cognitive tasks.21 Although
cognitive aspects are explicitly covered only in 1 ques-
tion in the FSS, the total FSS score appropriately
correlates with both cognitive and motor fatigue sub-
scales of the MFIS, which is why the results of our
study should be applicable for both motor and
cognitive aspects of fatigue.37 Nonetheless, it will be
very interesting to apply an instrument like the
Fatigue Scale for Motor and Cognitive functions,
which is more appropriate to dissect cognitive and
motor fatigue, in a future Phase IIb or III study.38
Finally, the study design included depression as as-
sessed by the BDI-IA as further exploratory end
point. However, after enrollment completion, the dis-
tribution of patients classified as depressed was
uneven between the groups, which is why we ab-
stained from further analyzing effects on depressive
symptoms in this study.
In light of the safety and tolerability of rTMS
treatment in MS-associated fatigue, our study
strongly suggests further investigating its potential
therapeutic efficacy and the underlying mechanisms.
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